Inhibikase shares surge 41.42% premarket on strategic shift to PAH and planned Phase 3 trial of IkT-001Pro.

Inhibikase surged 41.42% in premarket trading following the announcement of a strategic realignment prioritizing its PAH candidate IkT-001Pro. The company paused development of its Parkinson’s drug after a Phase 2 trial failed to meet primary endpoints, reallocating resources to its more promising pulmonary arterial hypertension program. This shift, coupled with plans to initiate the global Phase 3 "IMPROVE-PAH" trial in Q1 2026, signaled renewed focus and operational discipline. Additionally, the firm secured funding via a private placement to advance IkT-001Pro, bolstering investor confidence in its ability to achieve key clinical milestones. The move reflects a pivot to a higher-potential therapeutic area, reducing exposure to the high risks of neurodegenerative drug development and positioning the stock for potential re-rating based on future trial outcomes.